News
Topline results were announced from a phase 3 trial evaluating Cylembio (imsapepimut and etimupepimut, adjuvanted) in combination with pembrolizumab as a first-line treatment for advanced melanoma.
54m
Zacks Small Cap Research on MSNAEMD: Cohort 2 Enrollment Open; Initial Cohort 1 Data Analysis Expected Next Month
AEMD READ THE FULL AEMD RESEARCH REPORT ENROLLMENT FOR ONCOLOGY TRIAL COHORT 2 HAS COMMENCED Data Safety Monitoring Board Recommended AEMD Progress Trial Without Modification Aethlon Medical ...
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ('Kelun-Biotech', HKEX: 6990) announced that clinical data from a Phase II study evaluating novel TROP2 antibody-drug conjugate (ADC) sacituzumab ...
Crescent Biopharma is an early-stage biotech with a promising PD-1/VEGF bispecific antibody. Read why I rate CBIO stock as a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results